Emerald Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Emerald Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-48,307	Closed	-$1.48M	–	337
2015 Q4	$1.48M	Buy	48,307 +1,176	+2%	+$34.5K	0.07%	226
2015 Q3	$1.57M	Buy	47,131 +765	+2%	+$43.2K	0.08%	229
2015 Q2	$2.15M	Sell	46,366 -50,418	-52%	-$1.88M	0.1%	205
2015 Q1	$3.37M	Buy	96,784 +28,781	+42%	+$1.26M	0.17%	157
2014 Q4	$2.88M	Buy	68,003 +28,618	+73%	+$830K	0.15%	173
2014 Q3	$1.02M	Buy	+39,385	New	+$1.22M	0.06%	247

Other funds holding MRNS

CPV

Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers's MRNS Position: Q1 2016 in Review

Emerald Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2016, closing a stake of 48,307 shares — an estimated $1.48M sold.

Emerald Advisers first reported a position in MRNS in Q3 2014 and held it in 6 quarters. The position peaked at $3.37M in Q1 2015. 31 funds tracked by Wall St. Rank hold MRNS as of Q1 2016.

Emerald Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
Emerald Advisers sold 48,307 Marinus Pharmaceuticals, Inc shares in Q1 2016, an estimated $1.48M.
Emerald Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 6 quarters.
Emerald Advisers's Marinus Pharmaceuticals, Inc position peaked at $3.37M in Q1 2015.
31 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2016.

Based on Emerald Advisers's 13F filing for Q1 2016, filed 28 Apr 2016.